{'fraction_non_alphanumeric': 0.029644268774703556, 'fraction_numerical': 0.012845849802371542, 'mean_word_length': 5.535483870967742, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Outcome of Drug-Eluting Balloon Endovascular Treatment for Femoropopliteal Lesions in Patients with Intermittent Claudication

Background: Restenosis continues to be the great challenge of endovascular therapy, and drug-eluting balloons (DEB) havebeen developed to reduce it. The aim of this study was to analyze the results of this therapy.Methods: A retrospective analysis of 40 limbs with femoropopliteal lesions treated with DEB was conducted in patients withintermittent claudication.Results: Technical success was obtained in the 40 (100%) limbs treated, without evidence of serious complications relatedwith treatment, and with 92.5% of asymptomatic limbs during the follow-up period of 11.1 months. In three limbs, a newangioplasty was performed due to symptomatic recurrence.Conclusions: The drug-eluting balloon has proven to be a useful, safe and effective tool for the treatment of de novo and instentrestenosis lesions; however, TASC C-D lesions require the use of greater number of stents.